1.36
price down icon4.23%   -0.06
after-market Handel nachbörslich: 1.37 0.01 +0.74%
loading
Schlusskurs vom Vortag:
$1.42
Offen:
$1.43
24-Stunden-Volumen:
234.65K
Relative Volume:
0.17
Marktkapitalisierung:
$46.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.14M
KGV:
-2.5185
EPS:
-0.54
Netto-Cashflow:
$-3.99M
1W Leistung:
+1.49%
1M Leistung:
-4.90%
6M Leistung:
+15.74%
1J Leistung:
-68.37%
1-Tages-Spanne:
Value
$1.35
$1.4399
1-Wochen-Bereich:
Value
$1.35
$1.49
52-Wochen-Spanne:
Value
$1.12
$5.40

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Name
Firmenname
Telomir Pharmaceuticals Inc
Name
Telefon
786-396-6723
Name
Adresse
100 SE 2ND ST, MIAMI
Name
Mitarbeiter
5
Name
Twitter
Name
Nächster Verdiensttermin
2025-12-03
Name
Neueste SEC-Einreichungen
Name
TELO's Discussions on Twitter

Vergleichen Sie TELO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TELO
Telomir Pharmaceuticals Inc
1.36 48.82M 0 -16.14M -3.99M -0.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
463.86 119.17B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
796.55 84.19B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
398.29 52.77B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
788.49 48.98B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
175.97 36.31B 447.02M -1.18B -906.14M -6.1812

Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-21 Eingeleitet Rodman & Renshaw Buy

Telomir Pharmaceuticals Inc Aktie (TELO) Neueste Nachrichten

pulisher
05:16 AM

Is Telomir Pharmaceuticals Inc. stock a top momentum playJuly 2025 Summary & Growth Focused Entry Point Reports - ulpravda.ru

05:16 AM
pulisher
03:17 AM

Published on: 2026-01-10 12:17:57 - ulpravda.ru

03:17 AM
pulisher
Jan 09, 2026

Aug Movers: Why Telomir Pharmaceuticals Inc. stock is recommended by analystsGlobal Markets & Real-Time Market Trend Scan - ulpravda.ru

Jan 09, 2026
pulisher
Jan 08, 2026

Is Telomir Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Outlook & Advanced Swing Trade Entry Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Why retail investors favor Telomir Pharmaceuticals Inc. stockQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Trend Review: Why retail investors favor Telomir Pharmaceuticals Inc stockEarnings Growth Report & Step-by-Step Trade Execution Guides - moha.gov.vn

Jan 08, 2026
pulisher
Jan 08, 2026

Can Telomir Pharmaceuticals Inc. stock sustain revenue growthMerger & Acquisition Updates & Build Wealth With Expert Timing Advice - ulpravda.ru

Jan 08, 2026
pulisher
Jan 07, 2026

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models - The Florida Times-Union

Jan 07, 2026
pulisher
Jan 07, 2026

How Telomir Pharmaceuticals Inc. stock reacts to inflationary pressuresLow Risk Investment Ideas & Minimal Investment Portfolio Growth - ulpravda.ru

Jan 07, 2026
pulisher
Jan 06, 2026

Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It - Benzinga

Jan 06, 2026
pulisher
Jan 05, 2026

Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models - Investing.com Nigeria

Jan 05, 2026
pulisher
Jan 05, 2026

Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC - TipRanks

Jan 05, 2026
pulisher
Jan 05, 2026

Telomir Pharmaceuticals Reports Positive Preclinical Results for Telomir-1 - TradingView — Track All Markets

Jan 05, 2026
pulisher
Jan 05, 2026

Experimental breast cancer drug slows aggressive tumors in animal tests - Stock Titan

Jan 05, 2026
pulisher
Jan 01, 2026

Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationOptions Trading Strategies & Start Investing With Free Smart Watchlists - bollywoodhelpline.com

Jan 01, 2026
pulisher
Jan 01, 2026

Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models By Investing.com - Investing.com Nigeria

Jan 01, 2026
pulisher
Dec 31, 2025

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Lancaster Eagle-Gazette

Dec 31, 2025
pulisher
Dec 30, 2025

Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9%Here's What Happened - MarketBeat

Dec 30, 2025
pulisher
Dec 30, 2025

Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened - Defense World

Dec 30, 2025
pulisher
Dec 29, 2025

Is Telomir Pharmaceuticals Inc stock oversold or undervaluedRisk Management & Weekly Hot Stock Watchlists - moha.gov.vn

Dec 29, 2025
pulisher
Dec 26, 2025

Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Dec 26, 2025
pulisher
Dec 26, 2025

Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN

Dec 26, 2025
pulisher
Dec 22, 2025

Momentum Shift: What is the fair value of Telomir Pharmaceuticals Inc stock nowPortfolio Profit Report & AI Driven Stock Movement Reports - moha.gov.vn

Dec 22, 2025
pulisher
Dec 22, 2025

Telomir Pharmaceuticals sets CEO incentive awards and salary adjustment - Investing.com

Dec 22, 2025
pulisher
Dec 20, 2025

Chipmakers Recap: Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationQuarterly Market Summary & Accurate Technical Buy Alerts - ulpravda.ru

Dec 20, 2025

Finanzdaten der Telomir Pharmaceuticals Inc-Aktie (TELO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$106.87
price up icon 0.90%
$34.26
price up icon 1.87%
$118.64
price up icon 10.48%
$99.85
price up icon 1.01%
biotechnology ONC
$337.89
price up icon 5.47%
$175.97
price up icon 3.35%
Kapitalisierung:     |  Volumen (24h):